Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 4/20 | 0.32 |
| ▸ | PPARA | Q07869 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5414105 | 0.82 | PTPN1 (0.37) | PTPN1PTPN2MAPT | |
| SCHEMBL5414196 | 0.74 | PTPN1 (0.39) | PTPN1PTPN2 | |
| SCHEMBL5394413 | 0.73 | PTPN1 (0.42) | PTPN1PTPN2 | |
| SCHEMBL7623932 | 0.72 | PTPN1 (0.56) | PTPN1PTPN2PPARG | |
| SCHEMBL5404370 | 0.72 | PGK1 (0.42) | PTPN1PTPN2 | |
| SCHEMBL5391918 | 0.72 | PGK1 (0.42) | PTPN1PTPN2 | |
| SCHEMBL7625008 | 0.71 | PTPN1 (0.54) | PTPN1PTPN2ALDH1A1PPARG | |
| SCHEMBL4005577 | 0.71 | PGK1 (0.44) | PTPN1PTPN2 | |
| SCHEMBL5401089 | 0.71 | CETP (0.44) | PTPN1PTPN2 | |
| SCHEMBL5398161 | 0.70 | PTPN1 (0.43) | PTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163932-B2 | Aryldifluoromethylphosphonic acids for treatment of diabetes | MERCK FROSST CANADA & CO. (CA) | 2007-01-16 | — | — | US | disclosed |
| US-20040176330-A1 | Aryldifluoromethylphosphonic acids for treatment of diabetes | MERCK FROSST CANADA LTD. (CA) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176330-A1 | Aryldifluoromethylphosphonic acids for treatment of diabetes | PTPRF, PTPRO, PTP4A1 | PTPN1 16/4885PTPN2 27/4885ALDH1A1 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.